Otsuka Pharmaceutical Co., Ltd. announced that it has decided to terminate its global license agreements with Akebia Therapeutics, Inc. for vadadustat (generic name), under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). These licenses were signed in in December 2016 for the U.S. and April 2017 for Europe and other regions.

To read the full announcement, click here.